bromodeoxyuridine has been researched along with glucagon-like peptide 1 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, D; Egan, JM; Greig, NH; Lahiri, DK; Perry, T; Shaw, KT; Zhou, J | 1 |
Greig, NH; Holloway, HW; Li, Y; Mattson, MP; Tweedie, D | 1 |
Billeschou, A; Hunt, J; Kissow, H | 1 |
3 other study(ies) available for bromodeoxyuridine and glucagon-like peptide 1
Article | Year |
---|---|
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Topics: Amino Acid Sequence; Animals; Antimetabolites; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Differentiation; Cyclic AMP; DNA Replication; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Immunohistochemistry; L-Lactate Dehydrogenase; Molecular Sequence Data; Nerve Growth Factor; Neurodegenerative Diseases; PC12 Cells; Peptide Fragments; Peptides; Protein Precursors; Rats; Receptors, Glucagon; Stimulation, Chemical; Tetrazolium Salts; Thiazoles; Venoms | 2002 |
Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
Topics: Activating Transcription Factor 4; Adrenergic Agents; Apoptosis; bcl-2-Associated X Protein; Bromodeoxyuridine; Butadienes; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colforsin; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Neuroblastoma; Neuroprotective Agents; Nitriles; Oxidants; Oxidopamine; Peptides; Proto-Oncogene Proteins c-bcl-2; Receptors, Glucagon; Signal Transduction; Time Factors; Transfection; Venoms | 2010 |
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis.
Topics: Acute Disease; Adaptation, Physiological; Animals; Antineoplastic Agents; Biomarkers; Body Weight; Bromodeoxyuridine; Cell Proliferation; Disease Models, Animal; Endpoint Determination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Intestinal Mucosa; Intestine, Small; Mice, Inbred C57BL; Mucositis | 2019 |